SEC Form 4 · accession 0001715429-26-000007
First Tracks Biotherapeutics, Inc. · TRAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J. Anthony Ware
Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002091349
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 2, 2026 | M | 39,265 | $5.74 | A | 54,925 | D | |
| Common StockF1 | Sep 2, 2026 | S | 39,265 | $44.7764 | D | 15,660 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $5.74 | Sep 2, 2026 | M | 28,571 | D | — | Aug 21, 2027 | Common Stock | 28,571 | 0 | D |
| Stock Option (right to buy)F3,F2 | $5.74 | Sep 2, 2026 | M | 10,694 | D | — | Aug 21, 2027 | Common Stock | 10,694 | 0 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The stock option is fully vested.
- F3In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units.